by IPM staff
A new study from the Mayo Clinic finds that current screening protocols fail to catch a significant number of individuals with genetic mutations linked to hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome, which increase … Read more
Stereotactic ablative radiotherapy led to promising disease control in patients with metastatic gynecologic cancers, research showed.
by Brielle Benyon
Stereotactic ablative radiotherapy (SABR) can be a promising and tolerable way to control gynecologic cancers, according to research published in JAMA Oncology.
SABR is a type of radiation that is highly focused. It provides an intense … Read more
by Huntsman Cancer Institute at the University of Utah
Newswise — A landmark study from researchers at Huntsman Cancer Institute at the University of Utah (the U), the Spencer Fox Eccles School of Medicine at the U, and Boston University … Read more
by Stephen “Fred” Divers, MD, Chief Medical Officer & Julia Frydman, MD, Medical Director for Palliative Care
“I wish we had done this sooner.” This is something that we hear a lot from our patients and their families when they … Read more
Clearity Perspective: When people like Connie share their ovarian cancer experience, it helps others learn about resources and feel less alone. Connie speaks about how she benefitted from Clearity’s Steps Through OC program by receiving personalized Ovarian Cancer Counseling. Clearity … Read more
by Roman Fabbricatore
Fertility and sexual health services appear to be offered to cancer survivors less often than other services at CoC-accredited practices.
Enforcing survivorship standards may help centers provide services to address the needs of cancer survivors, according to … Read more
by Linda Wang
Physical activity can have many benefits for cancer survivors, from improving their quality of life to potentially making it less likely that their disease will come back. Yet studies have shown that many cancer survivors struggle to … Read more
—No difference in adverse events, clinical benefit, OS for patients with or without waivers
by Charles Bankhead
Patients who received protocol waivers in a clinical trial of targeted anticancer therapy had outcomes similar to those who met all enrollment criteria, a large retrospective review showed.
Patients who received waivers had a clinical benefit rate … Read more
Clearity’s Perspective: This article is written by a daughter whose mother was diagnosed with advanced ovarian cancer. She shares the story of her mother’s diagnosis and treatment and how her family handled learning of her mother’s inheritable genetic condition. Clearity
As presented at the ESMO Gynaecological Cancers Congress 2024 (Florence, 20–22 June), a post-hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial in patients with high folate receptor alpha (FRalpha), platinum-resistant ovarian cancer revealed that even those who required … Read more
By Sharon Worcester, MA
CHICAGO — Carlos, a 21-year-old, lay in a hospital bed, barely clinging to life. Following a stem cell transplant for leukemia, Carlos had developed a life-threatening case of graft-vs-host disease.
But Carlos’ mother had faith.
“I … Read more
Clearity’s Perspective: This article highlights that some people with ovarian cancer who live in certain geographic locations, like rural areas, may get treated at centers with less experience treating ovarian cancer and/or fewer resources to support whole-person needs. Clearity offers … Read more
by Wayne Kuznar
CHICAGO — Clinical activity and survival outcomes improved with the addition of ipilimumab (Yervoy) to nivolumab (Opdivo) in patients with ovarian or other gynecologic clear cell carcinomas, according to results from the non-comparative phase II BrUOG 354 … Read more
by Silas Inman
The addition of atezolizumab (Tecentriq) to single-agent non–platinum-based chemotherapy and bevacizumab (Avastin) did not provide any additional benefits for patients with recurrent ovarian cancer, according to the final analysis of the phase 3 AGO-OVAR 2.29/ENGOT-ov34 study (NCT03353831) … Read more
by The ASCO Post Staff
Some people with advanced epithelial ovarian cancer may safely avoid having their lymph nodes removed during surgery without it impacting their survival outcomes, helping to reduce the risk of postoperative complications. This research was presented … Read more
by Aaron Tallent
Key Points:
Led by Dr Melissa Merritt and Dr Nicola Meagher from the Daffodil Centre … Read more
by Van Andel Research Institute
Two types of endometriosis-related ovarian cancer arise from the same cells but likely at different stages of the menstrual cycle—a nuance that significantly influences treatment response, reports a recent study led by Van Andel Institute … Read more
Studying human genes to explore how changes in DNA might influence the onset, progression, and treatment of cancer has become a cornerstone in today’s world. Over the past 25 years, progress has ramped up due to technology advances, increased access … Read more
by Ariana Pelosci
Results of a recent study published in the Journal of Clinical Oncology highlighted the association of ovarian cancer with talcum powder (talc) use.1 The findings were from an extensive analysis of the Sister Study cohort.… Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
